The deal gives Lilly ownership of a small molecule that has inhibited tau aggregation in preclinical models.

The FDA cleared XenoTherapeutics to begin the first human clinical trial that uses live skin cells derived from pigs as a burn treatment.

Olympus pleaded guilty to not filing adverse event reports as required by the FDA for its duodenoscopes, agreeing to $85 million in fines and forfeiture.

Versant Ventures is unveiling Black Diamond Therapeutics, a biotech developing cancer treatments for an “undrugged and unexplored” group of oncogenes.

A phase 2 win for its lead drug in myasthenia gravis has Ra Pharma pressing the button on a $115 million public funding round.

The agreement sees Amgen pay a “modest” upfront fee to access Entera’s technology and commit to up to $270 million in milestones.

With Circassia failing to increase its free float, management has asked investors to vote in favor of a plan to delist from the main London exchange.

Aro Biotherapeutics raised $13 million to build its team and advance its centyrin pipeline, which includes a candidate for non-small cell lung cancer.

GenEdit raised $8.5 million to develop its proprietary polymer nanoparticle system for the delivery of gene therapy and gene editing.